Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen For 2.5- 3 Years Followed By Exemestane (Aromasin) For A Total Of 5 Years As Adjuvant Therapy For Postmenopausal, Receptor Positive, Node Negative or Node Positive Breast Cancer Patients

NCT00036270 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00036270
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00036270 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen For 2.5- 3 Years Followed By Exemestane (Aromasin) For A Total Of 5 Years As Adjuvant Therapy For Postmenopausal, Receptor Positive, Node Negative or Node Positive Breast Cancer Patients
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2001
Completion date
February 28, 2011
Enrollment
9,779 (actual)
Sites
179

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms